Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy

Area of Science:

• Immunology
• Virology
• Vaccinology

Background:

• Vaccinia virus (VV), a smallpox vaccine, has safety concerns due to immune evasion.
• VV infection disrupts antigen presentation pathways, including MHC class II (MHCII) and CD1d.
• CD74, an invariant chain, is crucial for MHCII and CD1d function and is downregulated during VV infection.

Purpose of the Study:

• To investigate if sustained CD74 expression can overcome VV-induced suppression of antigen presentation.
• To evaluate the impact of CD74 restoration on VV vaccine efficacy and immune responses.

Main Methods:

• Investigated VV's effect on CD74 levels in antigen-presenting cells.
• Assessed antigen presentation following ectopic CD74 expression or infection with recombinant VV encoding CD74 (mCD74-VV).
• Evaluated protection and antibody responses in mice immunized with mCD74-VV during VV challenge.

Main Results:

• Ectopic CD74 expression or mCD74-VV infection partially restored VV-inhibited MHCII antigen presentation.
• Virus-induced disruption of CD1d-mediated antigen presentation persisted despite sustained CD74 expression.
• Mice immunized with mCD74-VV showed enhanced protection and antibody responses against VV challenge.

Conclusions:

• Sustained CD74 expression can partially ameliorate VV-induced suppression of MHCII antigen presentation.
• Recombinant VV vaccines encoding CD74 may improve CD4+ T-cell responses to viral and tumor antigens.
• Further research into CD74-based strategies could enhance vaccine safety and efficacy.